Paper Details

  1. Home
  2. Paper Details

Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis.

Author: PangAlice, SenguptaNeil, TapaskarNatalie, WernerDebra A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Blood thinners are commonly used to prevent and treat blood clots, but they can cause bleeding in the digestive system. There's not enough information about how to best manage blood thinners after a patient has been hospitalized for this kind of bleeding. We need to better understand the risks of further bleeding, blood clots, and death after these events.
Paper Details　
Original Abstract of the Article :
Systemic anticoagulants are widely prescribed for prevention and treatment of thromboembolism, but are commonly complicated by gastrointestinal bleeding (GIB). Limited data exist on the management of anticoagulation after hospitalization for GIB and the subsequent risks of recurrent GIB, thromboembo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10620-020-06248-9

データ提供：米国国立医学図書館（NLM）

Resuming Anticoagulation After Gastrointestinal Bleeding: A Balancing Act

Gastrointestinal bleeding (GIB), a potential complication of anticoagulant therapy, can be a challenging desert landscape, requiring careful navigation. This systematic review and meta-analysis explore the impact of resuming anticoagulation after hospitalization for GIB. The focus is on the subsequent risk of recurrent GIB, thromboembolic events, and mortality.

Resuming Anticoagulation Might Offer a Protective Advantage

The study found that resuming anticoagulation after hospitalization for GIB was associated with a reduced risk of thromboembolic events and improved mortality. It's like finding a balance between the dangers of dehydration in the desert and the risks of venturing into the unknown. This research suggests that carefully managed anticoagulation resumption might offer a safer path for patients with a history of GIB.

Navigating Anticoagulation Decisions with Caution

This research highlights the importance of weighing the risks and benefits of anticoagulation therapy, particularly in patients with a history of GIB. Careful consideration of individual factors, such as bleeding risk and thromboembolic risk, is crucial. Just like a camel navigating a desert, finding the right balance and making informed decisions is essential for a safe and successful journey.

Dr.Camel's Conclusion

The desert of anticoagulation therapy can be a treacherous terrain, with potential for both benefits and risks. This research sheds light on the importance of carefully navigating anticoagulation decisions after hospitalization for GIB. While resuming anticoagulation might offer a protective advantage, it's crucial to work closely with a qualified medical professional to balance the risks and benefits and make informed decisions about your treatment.

Date :
  1. Date Completed 2021-04-28
  2. Date Revised 2021-04-28
Further Info :

Pubmed ID

32279174

DOI: Digital Object Identifier

10.1007/s10620-020-06248-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.